Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 4/20 | 0.73 |
| ▸ | GRM5 | P41594 | 2/20 | 0.59 |
| ▸ | MAOA | P21397 | 5/20 | 0.58 |
| ▸ | MAOB | P27338 | 5/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.58 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.57 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.57 |
| ▸ | PRKCI | P41743 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.54 |
| ▸ | TDP2 | O95551 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21222886 | 0.96 | HSD17B1 (0.68) | HSD17B1GRM5MAOAMAOBCYP2A6 | |
| SCHEMBL1745161 | 0.89 | HSD17B1 (0.71) | HSD17B1GRM5PARP10PARP11CYP1A2 | |
| SCHEMBL19685911 | 0.88 | HSD17B1 (0.61) | HSD17B1GRM5MAOAMAOBCYP2A6 | |
| SCHEMBL5211178 | 0.86 | MAOA (0.58) | HSD17B1GRM5MAOAMAOBCYP2A6 | |
| SCHEMBL29395799 | 0.86 | MAOA (0.58) | HSD17B1GRM5MAOAMAOBCYP2A6 | |
| SCHEMBL7506302 | 0.84 | HSD17B1 (0.71) | HSD17B1GRM5MAOAMAOBCYP2A6 | |
| SCHEMBL8170785 | 0.84 | HSD17B1 (0.71) | HSD17B1GRM5MAOAMAOBCYP2A6 | |
| SCHEMBL4090561 | 0.84 | HSD17B1 (1.00) | HSD17B1GRM5MAOAMAOBCYP2A6 | |
| SCHEMBL4418225 | 0.84 | HSD17B1 (0.71) | HSD17B1GRM5MAOAMAOBCYP2A6 | |
| SCHEMBL4428197 | 0.83 | PARP10 (0.61) | HSD17B1GRM5MAOAMAOBCYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0380038-B1 | 3-phenyl-5,6-dihydrobenz (C) - acridine-7-carboxylic acids and related compounds as cancer chemotherapeutic agents | DU PONT MERCK PHARMA (US) | 1995-06-28 | — | — | EP | claimed |
| EP-0380038-A2 | 3-phenyl-5,6-dihydrobenz (C) - acridine-7-carboxylic acids and related compounds as cancer chemotherapeutic agents | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1990-08-01 | — | — | EP | claimed |
| EP-4573086-A1 | METHANOGEN INHIBITORS | Agrizeronz Limited Partnership (NZ) | 2025-06-25 | — | — | EP | disclosed |
| CN-119998272-A | Methanogen inhibitors | 阿格里泽伦茨有限合伙公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2024039250-A1 | METHANOGEN INHIBITORS | PASTORAL GREENHOUSE GAS RESEARCH LIMITED (NZ) | 2024-02-22 | — | — | WO | disclosed |
| US-20220017541-A1 | INHIBITORS OF ARGINASE | Praxis Biotech LLC | 2022-01-20 | — | — | US | disclosed |
| EP-3883938-A1 | INHIBITORS OF ARGINASE | Praxis Biotech LLC (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3328872-B1 | ELECTROLUMINESCENT BRIDGED METAL COMPLEXES FOR USE IN ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2019-05-29 | — | — | EP | disclosed |
| EP-3328872-B1 | ELECTROLUMINESCENT BRIDGED METAL COMPLEXES FOR USE IN ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2019-05-29 | — | — | EP | disclosed |
| US-20180226591-A1 | ELECTROLUMINESCENT BRIDGED METAL COMPLEXES FOR USE IN ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2018-08-09 | — | — | US | disclosed |
| US-20180226591-A1 | ELECTROLUMINESCENT BRIDGED METAL COMPLEXES FOR USE IN ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2018-08-09 | — | — | US | disclosed |
| EP-0380038-B1 | 3-phenyl-5,6-dihydrobenz (C) - acridine-7-carboxylic acids and related compounds as cancer chemotherapeutic agents | DU PONT MERCK PHARMA (US) | 1995-06-28 | — | — | EP | disclosed |
| WO-1995003700-A1 | BRIDGED BIPHENYL CARBAPENEM ANTIBACTERIAL COMPOUNDS | MERCK & CO., INC. (US) | 1995-02-09 | — | — | WO | disclosed |
| US-5384317-A | Bactericides | MERCK & CO., INC. (US) | 1995-01-24 | — | — | US | disclosed |
| WO-1994028718-A1 | BRIDGED CARBAPENEM COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MERCK & CO., INC. (US) | 1994-12-22 | — | — | WO | disclosed |
| US-5374630-A | Bridged carbapenem antibacterial compounds | MERCK & CO., INC. (US) | 1994-12-20 | — | — | US | disclosed |
| US-5372993-A | Bridged carbapenem compounds, compositions containing such compounds and methods of use | MERCK & CO., INC. (US) | 1994-12-13 | — | — | US | disclosed |
| US-5002954-A | Leukemia, melanoma | DUPONT PHARMACEUTICALS COMPANY | 1991-03-26 | — | — | US | disclosed |
| EP-0380038-A2 | 3-phenyl-5,6-dihydrobenz (C) - acridine-7-carboxylic acids and related compounds as cancer chemotherapeutic agents | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1990-08-01 | — | — | EP | disclosed |
| US-4918077-A | ANTITUMOR AGENTS | E. I. DU PONT DE NEMOURS & CO., INC. (US) | 1990-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017541-A1 | INHIBITORS OF ARGINASE | ARG1, ARG2, ARGLU1 | HSD17B1 3180/4885GRM5 2737/4885MAOA 1017/4885 |
| US-20180226591-A1 | ELECTROLUMINESCENT BRIDGED METAL COMPLEXES FOR USE IN ELECTRONIC DEVICES | EED, SOD1, NBAS | HSD17B1 4401/4885GRM5 932/4885MAOA 1532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.